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Background 
Ovarian cancer has the highest mortality rate and is among the most common of female 
malignancies. Ovarian cancer cells are known to develop resistance to standard 
chemotherapeutic treatments.Gene silencing via RNA interferences (RNAi) mediated by 
short interfering RNA (siRNA) has enormous therapeutic potential for the treatment of cancer.  
Hypoxic inducible factor-1α (HIF-1α) is often overexpressed in cancers including 
ovarian cancer and it is associated with tumor aggressiveness, angiogenesis, cell migration, 
proliferation, survival, glucose metabolism, metastasis and drug resistance. It is predicted that 
HIF-1α suppression via siRNA technique would provide effective tumoricidal outcome in 
human ovarian cancer cells.  
The siRNA gene therapy is hindered because achieving sufficient concentration of 
siRNA at the tumor site(s) is difficult. siRNA has a high degradation rate in serum due to its 
physical characteristics, a rapid elimination by the renal pathway and a low permeability 
across cellular membranes. One way to enhance the delivery of siRNA to the site of action is 
a development of a suitable delivery platform with characteristics that enables 
biocompatibility, a high loading capacity, protection of siRNA during transport and a high 
targeting ability. 
Recently the delivery system for gene therapy has moved from viral vectors to synthetic 
and natural cationic polymers because viral vectors have potential to evoke immunogenic 
responses and can be hazardous during preparation. A representative cationic polysaccharide 
is a natural substance, chitosan. Nano-metric particles are easily formed by crosslinking 
chitosan with a counter ion such as tripolyphosphates (TPP), which particle provides a 
protection against degradation of loaded siRNA.  
There are problems in the use of chitosan for gene delivery. First, excessive positive 
charge that remains on the surface of the nanoparticles after formulation brings about 
interaction with red blood cells (RBCs), opsonization and activation of immune system 
resulting in elimination of them. Second, achieving a sufficient concentration of siRNA at the 
tumor site in a timely manner is difficult, as systemically administrated chitosan 
nanoparticles are only passively delivered there via the enhanced permeability and retention 
(EPR) effect. Third, uptake of chitosan nanoparticles by nonspecific endocytosis in tumor 
cells results in a low siRNA transfection efficiency. To address these problems, an active 
targeting system that can also aid the uptake of nanoparticles is required. 
In the present study we have emplyed folic acid (FA) as a targeting ligand because FA 
is harmless on normal cells, little immunogenic, inexpensive and stable under both in-vitro 
and in-vivo conditions. The expression level of the FA receptor is high in ovarian cancer cells, 
which promotes the receptor-mediated endocytosis of nanoparticles. The present study shows 
the potential utility of an siRNA delivery system with FA-PEG-COL nanoparticles 
encapsulating an HIF-1α siRNA for a targeted ovarian cancer gene therapy. 
 
Methods 
The chemical structure of FA-PEG-COL was verified with MALDI-TOF-MS (Applied 
Biosystems SCIEX TOF/TOF 5800), Fourier transform infrared spectroscopy (FT/IR-460, 
JASCO Corporation, Tokyo, Japan),  and 400 MHz NMR spectrometer (JNM-LA 400 
(Lambda 400) JEOL, Tokyo, Japan). The siRNA/FA-PEG-COL nanoparticles were obtained 
spontaneously via a modified ionic gelation method using TPP. Particle size and 
polydispersity index (PDI) of the different formulations were determined using a dynamic 
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light scatting analyzer (ELS-8000, Photal, Osaka, Japan). The zeta potential of the different 
formulations were determined by a laser Doppler microelectrophoresis Zetasizer (ELS 21, 
Photal, Osaka, Japan). Cellular uptake of formulations by OVK18#2 human ovarian cancer 
cells was measured using a FACS Calibur flow cytometer  (Becton-Dickinson, San Jose, CA, 
USA). The HIF1-α gene knockdown by siRNA was assessed at two levels, at the protein 
level by Western blotting and at the mRNA level using real time quantitative-PCR (RT-
qPCR).  In-vivo ovarian cancer xeno-graft accumulation efficiency of nanoparticles was 
examined with an IVIS
® 
Spectrum imaging system (Caliper LifeScience, Hopkinton, MA, 
USA). 
 
Results   
1) We have confirmed the chemical structure of the synthesized FA-PEG-COL. 
2) The particle size of siRNA/FA-PEG-COL is about 200 nm and the zeta potential is +8.4 
mV. The positive charge of COL was lowered by conjugation with FA-PEG as well as by 
loading siRNA.
3) In serum, rapid degradation of the unformulated siRNA was observed after 1 hour, while  
some siRNA remained intact with FA-PEG-COL nanoparticles over 36 hours. 
 
4) The RBC aggregation and haemolysis with FA-PEG-COL nanoparticles were markedly 
reduced compared with COL nanoparticles. FA-PEG-COL nanoparticles were significantly 
less toxic compared with COL nanoparticles.  
 
5) The FA receptor-mediated uptake of the FITC-FA-PEG-COL nanoparticles peaked at 9 
hours. The uptake of FITC-FA-PEG-COL nanoparticles was enhanced than that of FITC-
COL nanoparticles. 
 
6) Effect of HIF-1α knockdown by siRNA on proliferation of OVK18#2 ovarian cancer cells 
was more remarkable with FA-PEG-COL nanoparticles than COL nanoparticles. 
 
7) In nude mice bearing OVK18#2 ovarian cancer cells, FA-PEG-COL nanoparticles were 
significantly accumulated in tumor than COL nanoparticles. 
 
Discussion  
The effectiveness of using a FA-PEG-COL nanoparticles system for delivery of siRNA is 
shown for the potential anti-HIF-1α treatment of ovarian cancer. High encapsulating 
efficiency and good protection of siRNA from serum degradation with appropriate particle 
size were obtained with this system. Moreover, FA-PEG-COL nanoparticles have excellent 
tumor targeting ability with minimum uptake by the liver, implying that it has great potential 
not only for targeting the primary cancer site but also metastatic sites. The results shown here 
indicate that FA-PEG-COL nanoparticles containing siRNA may have good potential in use 
along with traditional chemotherapy and radiotherapy to achieve maximum tumoricidal 
activities. 
 
 
